Showing 2131-2140 of 3163 results for "".
- P&G to Unveil Improved Opte Precision Skincare System at CES 2020https://practicaldermatology.com/news/pg-to-unveil-improved-opte-precision-skincare-system-at-ces-2020/2460243/P&G Ventures, the startup studio within Procter & Gamble, is slated to showcase the Opte Precision Skincare System, the first personalized handheld inkjet printer to instantly make the appearance of skin's hyperpigmentation disappear and fade spots over time, at CES 2020. CE
- DermTech’s Pigmented Lesion Assay Receives Medicare Coveragehttps://practicaldermatology.com/news/dermtechs-pigmented-lesion-assay-receives-medicare-coverage/2460241/The Medicare Administrative Contractor Palmetto GBA MolDx issued a final local coverage determination for DermTech, Inc.'s Pigmented Lesion Assay (PLA). The PLA test is used to help rule out primary cutaneous melanoma and guide biopsy decisions of melanocytic skin lesions with one or more cli
- Avita Medical Receives U.S. FDA Investigational Device Exemption Approval of Clinical Feasibility Study to Evaluate RECELL System in Vitiligohttps://practicaldermatology.com/news/avita-medical-receives-us-fda-investigational-device-exemption-approval-of-clinical-feasibility-study-to-evaluate-recell-system-in-vitiligo/2460240/The U.S. Food and Drug Administration (FDA) approved AVITA Medical’s Investigational Device Exemption (IDE) application to conduct a feasibility study evaluating the safety and effectiveness of the RECELL Autologous Cell Harvesting Device (RECELL System) for repigmentation of depigmen
- FDA Approves Ortho Dermatologic’s Arazlo Lotion for Acnehttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-arazlo-lotion-for-acne/2460238/The FDA has approved the New Drug Application for ARAZLO (tazarotene) Lotion, 0.045%, for the topical treatment of acne vulgaris in patients nine years of age and older. Ortho Dermatologic’s ARAZLO is the first tazarotene acne treatment available in a lotion form,
- CBD Brands Initiates AD studyhttps://practicaldermatology.com/news/cbd-brands-initiates-ad-study-1/2460226/In the wake of the US Food and Drug Administration’s (FDA) recent revised warning about the risks of CBD products, CBD Brands is initiating a study to investigate a novel cannabidiol lotion for the treatment of atopic dermatitis (AD). The study aims to provide a preliminary assess
- Baring Private Equity Asia Agrees to Acquire Lumenishttps://practicaldermatology.com/news/baring-private-equity-asia-agrees-to-acquire-lumenis-1/2460222/Baring Private Equity Asia’s affiliated private equity funds are acquiring Lumenis. The transaction, which values Lumenis at an enterprise value of more than $1 billion, remains subject to the customary regulatory approval process. It is expected to be completed in early 2020. <
- Citing Underperformance, Hologic Sells Cynosure Medical Aesthetics Business for $205Mhttps://practicaldermatology.com/news/hologic-to-sell-cynosure-medical-aesthetics-business-for-205m/2460221/Hologic is selling Cynosure medical aesthetics business to an affiliate of investment funds managed by Clayton, Dubilier & Rice for a total purchase price of $205 million in cash, subject to certain closing adjustments. This is a tenth of the $1.6B that Hologic, a women's&n
- Kylie Jenner Sells $600 Million Majority Stake in Beauty Business to Cotyhttps://practicaldermatology.com/news/kylie-jenner-sells-600-million-majority-stake-in-beauty-business-to-coty/2460220/Kylie Jenner sold a majority stake in Kylie Cosmetics and Kylie Skin to Coty Inc. Under the terms of the agreement, Coty will acquire a 51 percent ownership in the partnership for $600M. The acquisition is expected to close in the third quarter of fiscal year 2020. Coty's family of
- Melanoma Rates Drop Sharply Among Teens, Young Adultshttps://practicaldermatology.com/news/melanoma-rates-drop-sharply-among-teens-young-adults/2460217/Cases of melanoma among U.S. adolescents and young adults declined markedly from 2006 to 2015 - even as the skin cancer's incidence continued to increase among older adults and the general population during the span, new research in JAMA Dermatology shows. The finding,
- Allergan Pays Exicure $25M upfront in Collaboration Deal to Develop Hair Loss Treatmenthttps://practicaldermatology.com/news/allergan-pays-exicure-25m-upfront-in-collaboration-deal-to-develop-hair-loss-treatment/2460216/Allergan Pharmaceuticals International Limited has entered into a global collaboration agreement with Exicure to discover and develop novel treatments for hair loss disorders based on Exicure’s proprietary SNA technology. Allergan will receive exclusive access and options to licen